Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alt a 1 is the major allergen protein of the fungus Alternaria alternata. It is an acidic, heat-stable homodimeric protein with a molecular weight of approximately 30 kDa and consists of two monomers (16.4 and 15.3 kDa). Structurally, it features an unusual β-barrel fold unique to fungi[2][1]. Alt a 1 is highly immunogenic and responsible for most IgE-mediated allergic reactions in individuals sensitized to A. alternata; up to 80–95% of asthmatic or allergic rhinitis patients sensitized to A. alternata show IgE reactivity to this protein[2]. Mechanistically, Alt a 1 induces strong innate immune responses in bronchial epithelial cells by activating toll-like receptor pathways (notably TLR4), leading to secretion of cytokines such as IL-8, IL-33, and IL-25[6][5][2]. In animal models and clinical studies, recombinant or purified Alt a 1 has been used as the active ingredient in allergen-specific immunotherapy (AIT) for asthma and allergic rhinitis caused by Alternaria exposure; these therapies can reduce symptoms and medication use while modulating immune cell populations involved in allergy (e.g., T follicular helper cells decrease; regulatory B cells increase)[3][4]. Alt a 1 has limited cross-reactivity with other allergens but shares some structural similarity with human siderocalin proteins[2]. Its biological function within fungi remains unclear but may involve ligand transport or spore germination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alt a 1.